NasdaqGM:VCYTBiotechs
Is Veracyte (VCYT) Undervalued As Raised 2026 Outlook And Q2 Earnings Lift Interest?
Veracyte (VCYT) is back on investor radar after raising its 2026 revenue outlook and reporting second quarter results that turned a prior net loss into net income, supported by new cancer diagnostics launches.
See our latest analysis for Veracyte.
The raised 2026 revenue outlook and strong second quarter earnings have been followed by a sharp pullback, with Veracyte’s share price down 22.5% over one day and 18.9% over 30 days. However, the 90 day share price return of 40.0% and one year total...